At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
In Brief
A Phase 2 clinical trial evaluating Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, and 10 other interventions for Primary Myelofibrosis and Secondary Myelofibrosis. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This phase II trial studies how well giving a JAK inhibitor before a donor stem cell transplant works in treating patients with myelofibrosis that developed without another condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed for cell growth. Giving a JAK inhibitor such as ruxolitinib before a donor stem cell transplant may help reduce symptoms of myelofibrosis such as inflammation and enlargement of the spleen, improve the patient's general physical condition, and prevent complications from occurring after the transplant. Infusing healthy stem cells from a donor into the patient may help the patient's bone marrow work normally and make stem cells, red blood cells, white blood cells, and platelets. Giving a JAK inhibitor before a donor stem cell transplant may help improve transplant outcomes in patients with myelofibrosis.
Study Details
Timeline
Interventions
Undergo allogeneic hematopoietic stem cell transplant
Given IV
Given IV
Given IV
Correlative studies
Given IV
Given IV
Given IV or PO
Given PO
Given IV or PO
Undergo TBI
Undergo umbilical cord blood transplant